Gout therapeutics and drug delivery

IF 10.5 1区医学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Journal of Controlled Release Pub Date : 2023-10-01 DOI:10.1016/j.jconrel.2023.09.011

Xiuju Peng , Xiaotong Li , Bing Xie , Yaoyao Lai , Alejandro Sosnik , Hamza Boucetta , Zhongjian Chen , Wei He

{"title":"Gout therapeutics and drug delivery","authors":"Xiuju Peng , Xiaotong Li , Bing Xie , Yaoyao Lai , Alejandro Sosnik , Hamza Boucetta , Zhongjian Chen , Wei He","doi":"10.1016/j.jconrel.2023.09.011","DOIUrl":null,"url":null,"abstract":"<div><p><span>Gout is a common inflammatory arthritis caused by persistently elevated </span>uric acid<span> levels. With the improvement of people's living standards, the consumption of processed food and the widespread use of drugs that induce elevated uric acid, gout rates are increasing, seriously affecting the human quality of life, and becoming a burden to health systems worldwide. Since the pathological mechanism of gout has been elucidated, there are relatively effective drug treatments in clinical practice. However, due to (bio)pharmaceutical shortcomings of these drugs, such as poor chemical stability and limited ability to target the pathophysiological pathways, traditional drug treatment strategies show low efficacy and safety. In this scenario, drug delivery systems (DDS) design that overcome these drawbacks is urgently called for. In this review, we initially describe the pathological features, the therapeutic targets, and the drugs currently in clinical use and under investigation to treat gout. We also comprehensively summarize recent research efforts utilizing lipid, polymeric and inorganic carriers to develop advanced DDS for improved gout management and therapy.</span></p></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":null,"pages":null},"PeriodicalIF":10.5000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365923005977","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Gout is a common inflammatory arthritis caused by persistently elevated uric acid levels. With the improvement of people's living standards, the consumption of processed food and the widespread use of drugs that induce elevated uric acid, gout rates are increasing, seriously affecting the human quality of life, and becoming a burden to health systems worldwide. Since the pathological mechanism of gout has been elucidated, there are relatively effective drug treatments in clinical practice. However, due to (bio)pharmaceutical shortcomings of these drugs, such as poor chemical stability and limited ability to target the pathophysiological pathways, traditional drug treatment strategies show low efficacy and safety. In this scenario, drug delivery systems (DDS) design that overcome these drawbacks is urgently called for. In this review, we initially describe the pathological features, the therapeutic targets, and the drugs currently in clinical use and under investigation to treat gout. We also comprehensively summarize recent research efforts utilizing lipid, polymeric and inorganic carriers to develop advanced DDS for improved gout management and therapy.

Abstract Image

查看原文本刊更多论文

痛风治疗和药物输送。

痛风是一种常见的炎症性关节炎，由持续升高的尿酸水平引起。随着人们生活水平的提高、加工食品的消费以及导致尿酸升高的药物的广泛使用，痛风发病率正在上升，严重影响人类生活质量，并成为世界各地卫生系统的负担。由于痛风的病理机制已经阐明，临床上有相对有效的药物治疗方法。然而，由于这些药物的（生物）药物缺点，如化学稳定性差和靶向病理生理途径的能力有限，传统的药物治疗策略显示出较低的疗效和安全性。在这种情况下，迫切需要克服这些缺点的药物递送系统（DDS）设计。在这篇综述中，我们初步描述了痛风的病理特征、治疗靶点以及目前临床使用和正在研究的治疗痛风的药物。我们还全面总结了最近利用脂质、聚合物和无机载体开发先进DDS以改善痛风管理和治疗的研究工作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Controlled Release 医学-化学综合

CiteScore

18.50

自引率

5.60%

发文量

700

审稿时长

39 days

期刊介绍： The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System. Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.